Daiichi Sankyo Co Ltd (4568) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
206
About the Report
About the Report
Summary
Daiichi Sankyo Company Ltd (Daiichi Sankyo) is a holding company that carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over-the-counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrologic, diabetic, metabolic and infectious diseases; and various types of cancers. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.
Daiichi Sankyo Co Ltd (4568)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Daiichi Sankyo Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 8
List of Figures 9
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14
Daiichi Sankyo Co Ltd, Medical Devices Deals, 2012 to YTD 2018 16
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deal Details 23
Venture Financing 23
Ambit Biosciences Raises USD 25 Million In First Tranche Of Venture Financing 23
Ambit Biosciences Raises USD 7.07 Million In Venture Financing 25
Partnerships 26
Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 26
Daiichi Sankyo Enters into Co-Development Agreement with Merck Sharp & Dohme 27
PhoreMost Enters into Collaboration Agreement with Plexxikon 28
Daiichi Sankyo Enters into Agreement with DarwinHealth 29
Evotec Enters into Agreement with U3 Pharma 30
Vernalis and Daiichi Sankyo Enter into Agreement 31
Daiichi Sankyo and Puma Biotech Enter into Research Agreement with Memorial Sloan Kettering Cancer Center 32
Daiichi Sankyo and Glycotope Enter into Option Agreement 33
Daiichi Sankyo Partners with Saitama Medical University 34
National Cancer Center, JVCKENWOOD, Sysmex and Daiichi Sankyo Enter into Agreement 35
University of Texas MD Anderson and Daiichi Sankyo Enter into Research Agreement 36
Bristol-Myers Squibb and Daiichi Sankyo Enter into Agreement 37
Daiichi Sankyo Enters into Agreement with Kyukyu Pharma 38
Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Enter into Research Agreement 39
ProLynx Enters into Partnership with Daiichi Sankyo 40
Daiichi Sankyo Enters into Research Agreement with Drugs for Neglected Diseases initiative 41
National Institutes of Biomedical Innovation, Daiichi Sankyo and Mitsubishi UFJ Capital Form Joint Venture 42
Daiichi Sankyo Enters into Research Agreement with Dana-Farber Cancer Institute 43
Daiichi Sankyo Enters into Research Agreement with Medicines for Malaria Venture 44
Daiichi Sankyo Enters into Research Agreement with AgonOx 45
Amgen and Daiichi Sankyo Enter into Agreement 46
Daiichi Sankyo Enters Into Marketing Agreement With Servier Canada 47
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 48
Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 50
Asahikawa Medical University, Daiichi Sankyo and Mitsubishi UFJ Capital Form Joint Venture 51
Daiichi Sankyo Enters into Co-Marketing Agreement with Merck 52
Daiichi Sankyo Enters into Co-Marketing Agreement with Daewoong Pharma 53
Simcere Pharma Enters into Agreement with Daiichi Sankyo 54
Daiichi Sankyo, Japan Vaccine and Sanofi Enter into Co-Marketing Agreement 55
Daiichi Sankyo Partners with Cytoo 56
Biohit Enters into Distribution Agreement with Daiichi Sankyo 57
Daiichi Sankyo Enters into Agreement with Maruishi Pharma 58
Plexxikon Enters into Agreement with Merck 59
AstraZeneca Enters into Commercialization Agreement with Daiichi Sankyo for Movantik 60
Daiichi Sankyo Enters into Co-Marketing Agreement with UCB Biopharma for Lacosamide 61
Portola Pharma Enters into Expanded Agreement with Daiichi Sankyo 62
Sanford Burnham Enters into Co-Development Agreement with Daiichi Sankyo 63
MRC Technology Enters into Drug Discovery Agreement with Daiichi Sankyo 64
Agendia Enters into Co-Development Agreement with Daiichi Sankyo 65
Daiichi Sankyo Enters into Co-Promotion Agreement with Daewoong Pharma For Olostar 66
Daiichi Sankyo Enters Into Drug Discovery Agreement With Lead Discovery Center 67
Daiichi Sankyo Enters Into Co-Development Agreement With UCSF 68
Daiichi Sankyo and UMN Pharma Enter into Research Agreement for Norovirus Vaccine 69
Abcheck Enters Into Research Agreement With U3 Pharma 70
Daiichi Sankyo Forms Joint Venture With Innovation Network Corporation And Mitsubishi UFJ Capital 71
Daiichi Sankyo Enters Into Agreement With Amplimmune To Develop Therapy For Autoimmune Disease 72
PeptiDream Enters into Drug Discovery Agreement with Daiichi Sankyo 73
Daiichi Sankyo Venezuela Enters Into Co-Marketing Agreement With Ranbaxy Labs 74
Daiichi Sankyo Enters Into Co-Development Agreement With National Cancer Center Hospital East 75
Daiichi Sankyo Enters Into Co-Marketing Agreement With Terapia Ranbaxy For Sevikar 76
Daiichi Sankyo Enters Into Co-Development Agreement With NGM Biopharma For Diabetes Drugs 77
Mitsubishi Tanabe Pharma Expands its Co-Marketing Agreement with Daiichi Sankyo for MP-513 And TA-7284 78
Daiichi Sankyo And GlaxoSmithKline to Dissolve Joint Venture 79
Daiichi Sankyo Enters Into Co-Development Agreement With Terumo For Intradermal Vaccine 80
Merger 81
Daiichi Sankyo to Merge with Asubio Pharma 81
Licensing Agreements 82
Daiichi Sankyo Enters into Licensing Agreement with Glycotope 82
Menarini Enters into Licensing Agreement with Daiichi Sankyo 83
Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 84
Daiichi Sankyo Enters into Licensing Agreement with Boston Pharma 85
Daiichi Sankyo to Enter into Licensing Agreement with Inspirion Delivery Sciences 86
Daiichi Sankyo Enters into Licensing Agreement with Sosei Group 87
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 88
Daiichi Sankyo Enters into Licensing Agreement with Kite Pharma 89
Daiichi Sankyo Enters into Licensing Agreement with Inspirion Delivery Sciences 90
Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 91
Zymeworks Enters into Licensing Agreement with Daiichi Sankyo 92
Daiichi Sankyo Enters into Licensing Agreement with Cell Therapy 93
Daiichi Sankyo Enters into Licensing Agreement with MedImmune for FluMist 94
Dainippon Sumitomo Pharma Enters into Licensing Agreement with Daiichi Sankyo 95
Odonate Therapeutics Enters Into Licensing Agreement With Daiichi Sankyo 96
Affibody Enters Into Licensing Agreement With Daiichi Sankyo For Albumod 97
Equity Offering 98
Daiichi Sankyo Invests in Cuorips 98
Daiichi Sankyo to Invest in USD196.7 Million in Luitpold Pharma 99
Daiichi Sankyo Raises USD3.6 Billion in Public Offering of Shares of Sun Pharma 100
Ambit Biosciences Completes Private Placement Of Shares For USD 25 Million 101
Ambit Biosciences Completes IPO Of Shares For USD 65 Million 102
Debt Offering 104
Daiichi Sankyo to Raise USD713.4 Million in Public Offering of 0.81% 5th Series Bonds Due 2036 104
Daiichi Sankyo to Raise USD237.8 Million in Public Offering of 1.2% 6th Series Bonds Due 2046 105
Asset Transactions 106
Alfresa Pharma to Acquire 41 Products from Daiichi Sankyo 106
Amring Pharma Acquires Six ANDAs from Luitpold Pharma and AlphaForce 107
Egalet Acquires SPRIX Nasal Spray from Luitpold Pharma 108
CMIC CMO Completes Acquisition Of Research Equipment From Daiichi Sankyo 110
Acquisition 111
Sun Pharma Acquires Ranbaxy Labs for USD4 Billion 111
Daiichi Sankyo Acquires Majority Stake in Ambit Biosciences 114
Daiichi Sankyo Acquires Shanghai Xinshengyuan Pharma From Xinshengyuan Pharma 116
Daiichi Sankyo Plans To Acquire India-Based Pharma Company 117
Daiichi Sankyo Co Ltd-Key Competitors 118
Daiichi Sankyo Co Ltd-Key Employees 119
Daiichi Sankyo Co Ltd-Locations And Subsidiaries 121
Head Office 121
Other Locations & Subsidiaries 121
Joint Venture 124
Recent Developments 125
Strategy And Business Planning 125
Aug 01, 2018: Daiichi Sankyo transfers 41 products to Alfresa Pharma 125
Apr 27, 2018: Daiichi Sankyo to Reorganize Kitasato Daiichi Sankyo Vaccine into Specialized Manufacturing Subsidiary 126
Feb 23, 2018: Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2018 127
Jan 09, 2018: Daiichi Sankyo to Convert Kitasato Daiichi Sankyo Vaccine into Wholly Owned Subsidiary 129
Sep 07, 2017: Daiichi Sankyo Announces Organizational Restructuring Effective as of October 1, 2017 130
Feb 24, 2017: Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2017 131
Feb 15, 2017: Daiichi Sankyo Strengthens Authorized Generic Business through Daiichi Sankyo Espha 133
Feb 10, 2017: Daiichi Sankyo Announces Further Reorganization of its Research & Development Structure 135
Corporate Communications 136
May 11, 2018: Daiichi Sankyo Announces Changes to Representative Directors and Members of the Audit and Supervisory Board 136
Jan 31, 2017: Daiichi Sankyo Announces New Chairman and President 137
Legal and Regulatory 138
Jun 06, 2018: Daiichi Sankyo's U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In 138
Mar 30, 2018: Daiichi Sankyo Agrees to Modify the Terms of the Settlement Program for U.S. Olmesartan Products Liability Litigation 139
Aug 01, 2017: Daiichi Sankyo Announces Settlement Agreement on U.S. Products Liability Litigation 140
Government and Public Interest 141
Jul 11, 2017: Daiichi Sankyo Selected for Ninth Consecutive Year as Constituent of FTSE4Good Global Index by FTSE Russell 141
Jul 03, 2017: 15th Takamine Memorial Daiichi Sankyo Prize Winner Announced 142
Jun 16, 2017: Daiichi Sankyo’s Japan Research Foundation for Clinical Pharmacology 10th Annual Clinical Pharmacology Research Award 143
Jan 18, 2017: Daiichi Sankyo Announces Participation in the Global Initiative, Access Accelerated 144
Product News 145
Oct 12, 2017: Daiichi Sankyo Announces Support from the Japan Agency for Medical Research and Development’s CiCLE Program for Its Genetic Vaccine Platform, and Commencement of an Industry- Government-Academia Research & Development Collaboration for Development Vaccines Using the Platform 145
Oct 11, 2017: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct “JOINUS,” a New Drug Discovery Program Using Drug-Repositioning Compound Library 146
09/03/2018: The FDA attributed the designation of innovative therapy to quizartinib, a FLT3 inhibitor for the treatment of relapsed / refractory AML from Daiichi Sankyo 147
08/30/2017: "Tazopipe Notice of additional adaptation acquisition of the blending static for the Note" Meiji 148
Aug 29, 2018: ProLynx and Daiichi Sankyo announce the development of technology for half-life extension of small molecules in the eye 149
08/29/2017: FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast Cancer 150
08/01/2018: Daiichi Sankyo announce FDA grants breakthrough therapy designation to Daiichi Sankyo’s FLT3 inhibitor Quizartinib for relapsed/refractory FLT3-ITD AML 151
Jul 20, 2017: Daiichi Sankyo Opens Applications for Investigator-Initiated Studies Program 152
Jun 15, 2017: Daiichi Sankyo Launches New Generic Drugs through Its Daiichi Sankyo Espha Subsidiary 153
04/20/2018: Vaxart Announces $5 Million Inavir Revenue Milestone 156
Mar 30, 2017: Daiichi Sankyo Announces Collaborative Research on Drugs for Neglected Tropical Diseases 157
03/26/2018: Japanese Government to Stockpile Inavir Anti-influenza Drug for Combatting Pandemic Influenza Threats in Japan 158
Mar 16, 2017: The National Institutes of Biomedical Innovation, Health and Nutrition, Daiichi Sankyo,and Mitsubishi UFJ Capital Announce Open Innovation Research on New Cancer Immunotherapy 159
01/18/2017: ß- lactamase inhibitor formulated antibiotic formulation "Tazopipe Notice of additional indications and effect the acquisition of blending static for the Note" Meiji "" 160
01/18/2017: Daiichi Sankyo Initiates Phase 1/2 Study of Novel Antibody Drug Conjugate U3-1402 in Patients with HER3-Positive Metastatic or Unresectable Breast Cancer 161
Product Approvals 162
Feb 15, 2018: Daiichi Sankyo Submits Marketing Application for Mirogabalin in Japan 162
Clinical Trials 163
Jul 06, 2018: Northwestern University: Clinical Trial Show Promise in Leukemia 163
Jun 16, 2018: Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyos Quizartinib Significantly Prolongs Overall Survival as Single Agent Compared to Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations 164
Jun 12, 2018: EHA Late-Breaking, Plenary Presentation: Quizartinib Significantly Prolongs Overall Survival in Pivotal, Phase 3 AML Study 166
Jun 06, 2018: Daiichi Sankyo to Present Late-Breaking Phase 3 Data for Single Agent Quizartinib in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations at Plenary Session at EHA 2018 167
May 08, 2018: Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study) 169
Dec 28, 2017: Odonate Therapeutics Announces Initiation of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Locally Advanced or Metastatic Breast Cancer 170
Dec 22, 2017: Glycotope Initiates Phase Ib Trial of Combination of Proprietary Anti-Tumor Antibodies 172
Dec 11, 2017: Daiichi Sankyo Presents Phase 1 Data for EZH1/2 Dual Inhibitor DS-3201 in Patients with Non-Hodgkin Lymphomas at the 59th Annual Meeting of the American Society of Hematology 173
Dec 07, 2017: Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Breast Cancer at San Antonio Breast Cancer Symposium 175
Nov 20, 2017: Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Advanced Gastric Cancer 176
Nov 14, 2017: Daiichi Sankyo Announces Presentation on its Investigational Agent DS-3201 at ASH 178
Nov 14, 2017: Daiichi Sankyo Announces Presentation on its Investigational Agent Quizartinib dihydrochloride at ASH 179
Nov 14, 2017: Daiichi Sankyo to Present Updated DS-8201 Data at SABCS 180
Sep 11, 2017: Daiichi Sankyo Presents New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors at European Society for Medical Oncology (ESMO) 2017 Congress 181
Sep 06, 2017: Sanford Burnham Prebys and Daiichi Sankyo Announce Enrollment of First Subject in a Phase 1 Clinical Trial of DS-1211 in Healthy Volunteers 183
Aug 31, 2017: Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabalin in Diabetic Peripheral Neuropathic Pain 184
Aug 31, 2017: Daiichi Sankyo Presents Data on DS-1205 at the European Society for Medical Oncology 2017 Congress 185
Aug 31, 2017: Daiichi Sankyo Showcases New Insights on DS-8201 at the European Society for Medical Oncology 2017 Congress 186
Aug 31, 2017: Daiichi Sankyo to Present Data on leukemia Drug Candidate Quizartinib at the European Society for Medical Oncology 2017 Congress 187
Aug 29, 2017: Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Metastatic Breast Cancer 188
Jun 30, 2017: Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes 189
Jun 05, 2017: New Precision Medicine Data on DS-8201 in HER2-Expressing Breast Cancer Revealed at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting 191
Mar 29, 2017: Daiichi Sankyo Cancer Enterprise Showcases New Data on DS-8201 at American Association for Cancer Research 2017 Annual Meeting 193
Mar 29, 2017: Daiichi Sankyo Cancer Enterprise Showcases New Data on U3-1402 at American Association for Cancer Research 2017 Annual Meeting 194
Mar 29, 2017: Daiichi Sankyo Showcases New Data on EZH1/2 Inhibition at American Association for Cancer Research 2017 Annual Meeting 195
Other Significant Developments 196
Oct 09, 2018: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of "Joinus", a joint research program to discover new drugs using drug-repositioning compound library 196
Feb 28, 2018: Daiichi Sankyo Aligns U.S. Commercial Operations to Current Portfolio and Upcoming Cancer Pipeline 197
Oct 30, 2017: Daiichi Sankyo Working with Berkeley Lights' Beacon OptoFluidic Platform for Cell Line Development 198
Sep 26, 2017: Daiichi Sankyo Announces TaNeDS Global 2018 Collaborative Drug Discovery Program 199
Apr 27, 2017: Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio 201
Mar 23, 2017: Daiichi Sankyo to Facilitate New Drug Discovery in 2017 through Collaborative Research and Grants 202
Feb 14, 2017: PeptiDream Announces the Selection of Development Candidate from Discovery Collaboration with Daiichi Sankyo 203
Feb 02, 2017: Daiichi Sankyo Announces Continuation of Mobile Healthcare Field Clinic Service Aimed at Improving Healthcare Access in Tanzania 204
Jan 10, 2017: Daiichi Sankyo Announces Reorganization of Research & Development System 205
Appendix 206
Methodology 206
About GlobalData 206
Contact Us 206
Disclaimer 206
List of Figure
List of Figures
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 12
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14
Daiichi Sankyo Co Ltd, Medical Devices Deals, 2012 to YTD 2018 16
List of Table
List of Tables
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
Daiichi Sankyo Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 14
Daiichi Sankyo Co Ltd, Medical Devices Deals, 2012 to YTD 2018 16
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17
Ambit Biosciences Raises USD 25 Million In First Tranche Of Venture Financing 23
Ambit Biosciences Raises USD 7.07 Million In Venture Financing 25
Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 26
Daiichi Sankyo Enters into Co-Development Agreement with Merck Sharp & Dohme 27
PhoreMost Enters into Collaboration Agreement with Plexxikon 28
Daiichi Sankyo Enters into Agreement with DarwinHealth 29
Evotec Enters into Agreement with U3 Pharma 30
Vernalis and Daiichi Sankyo Enter into Agreement 31
Daiichi Sankyo and Puma Biotech Enter into Research Agreement with Memorial Sloan Kettering Cancer Center 32
Daiichi Sankyo and Glycotope Enter into Option Agreement 33
Daiichi Sankyo Partners with Saitama Medical University 34
National Cancer Center, JVCKENWOOD, Sysmex and Daiichi Sankyo Enter into Agreement 35
University of Texas MD Anderson and Daiichi Sankyo Enter into Research Agreement 36
Bristol-Myers Squibb and Daiichi Sankyo Enter into Agreement 37
Daiichi Sankyo Enters into Agreement with Kyukyu Pharma 38
Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Enter into Research Agreement 39
ProLynx Enters into Partnership with Daiichi Sankyo 40
Daiichi Sankyo Enters into Research Agreement with Drugs for Neglected Diseases initiative 41
National Institutes of Biomedical Innovation, Daiichi Sankyo and Mitsubishi UFJ Capital Form Joint Venture 42
Daiichi Sankyo Enters into Research Agreement with Dana-Farber Cancer Institute 43
Daiichi Sankyo Enters into Research Agreement with Medicines for Malaria Venture 44
Daiichi Sankyo Enters into Research Agreement with AgonOx 45
Amgen and Daiichi Sankyo Enter into Agreement 46
Daiichi Sankyo Enters Into Marketing Agreement With Servier Canada 47
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 48
Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 50
Asahikawa Medical University, Daiichi Sankyo and Mitsubishi UFJ Capital Form Joint Venture 51
Daiichi Sankyo Enters into Co-Marketing Agreement with Merck 52
Daiichi Sankyo Enters into Co-Marketing Agreement with Daewoong Pharma 53
Simcere Pharma Enters into Agreement with Daiichi Sankyo 54
Daiichi Sankyo, Japan Vaccine and Sanofi Enter into Co-Marketing Agreement 55
Daiichi Sankyo Partners with Cytoo 56
Biohit Enters into Distribution Agreement with Daiichi Sankyo 57
Daiichi Sankyo Enters into Agreement with Maruishi Pharma 58
Plexxikon Enters into Agreement with Merck 59
AstraZeneca Enters into Commercialization Agreement with Daiichi Sankyo for Movantik 60
Daiichi Sankyo Enters into Co-Marketing Agreement with UCB Biopharma for Lacosamide 61
Portola Pharma Enters into Expanded Agreement with Daiichi Sankyo 62
Sanford Burnham Enters into Co-Development Agreement with Daiichi Sankyo 63
MRC Technology Enters into Drug Discovery Agreement with Daiichi Sankyo 64
Agendia Enters into Co-Development Agreement with Daiichi Sankyo 65
Daiichi Sankyo Enters into Co-Promotion Agreement with Daewoong Pharma For Olostar 66
Daiichi Sankyo Enters Into Drug Discovery Agreement With Lead Discovery Center 67
Daiichi Sankyo Enters Into Co-Development Agreement With UCSF 68
Daiichi Sankyo and UMN Pharma Enter into Research Agreement for Norovirus Vaccine 69
Abcheck Enters Into Research Agreement With U3 Pharma 70
Daiichi Sankyo Forms Joint Venture With Innovation Network Corporation And Mitsubishi UFJ Capital 71
Daiichi Sankyo Enters Into Agreement With Amplimmune To Develop Therapy For Autoimmune Disease 72
PeptiDream Enters into Drug Discovery Agreement with Daiichi Sankyo 73
Daiichi Sankyo Venezuela Enters Into Co-Marketing Agreement With Ranbaxy Labs 74
Daiichi Sankyo Enters Into Co-Development Agreement With National Cancer Center Hospital East 75
Daiichi Sankyo Enters Into Co-Marketing Agreement With Terapia Ranbaxy For Sevikar 76
Daiichi Sankyo Enters Into Co-Development Agreement With NGM Biopharma For Diabetes Drugs 77
Mitsubishi Tanabe Pharma Expands its Co-Marketing Agreement with Daiichi Sankyo for MP-513 And TA-7284 78
Daiichi Sankyo And GlaxoSmithKline to Dissolve Joint Venture 79
Daiichi Sankyo Enters Into Co-Development Agreement With Terumo For Intradermal Vaccine 80
Daiichi Sankyo to Merge with Asubio Pharma 81
Daiichi Sankyo Enters into Licensing Agreement with Glycotope 82
Menarini Enters into Licensing Agreement with Daiichi Sankyo 83
Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 84
Daiichi Sankyo Enters into Licensing Agreement with Boston Pharma 85
Daiichi Sankyo to Enter into Licensing Agreement with Inspirion Delivery Sciences 86
Daiichi Sankyo Enters into Licensing Agreement with Sosei Group 87
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 88
Daiichi Sankyo Enters into Licensing Agreement with Kite Pharma 89
Daiichi Sankyo Enters into Licensing Agreement with Inspirion Delivery Sciences 90
Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 91
Zymeworks Enters into Licensing Agreement with Daiichi Sankyo 92
Daiichi Sankyo Enters into Licensing Agreement with Cell Therapy 93
Daiichi Sankyo Enters into Licensing Agreement with MedImmune for FluMist 94
Dainippon Sumitomo Pharma Enters into Licensing Agreement with Daiichi Sankyo 95
Odonate Therapeutics Enters Into Licensing Agreement With Daiichi Sankyo 96
Affibody Enters Into Licensing Agreement With Daiichi Sankyo For Albumod 97
Daiichi Sankyo Invests in Cuorips 98
Daiichi Sankyo to Invest in USD196.7 Million in Luitpold Pharma 99
Daiichi Sankyo Raises USD3.6 Billion in Public Offering of Shares of Sun Pharma 100
Ambit Biosciences Completes Private Placement Of Shares For USD 25 Million 101
Ambit Biosciences Completes IPO Of Shares For USD 65 Million 102
Daiichi Sankyo to Raise USD713.4 Million in Public Offering of 0.81% 5th Series Bonds Due 2036 104
Daiichi Sankyo to Raise USD237.8 Million in Public Offering of 1.2% 6th Series Bonds Due 2046 105
Alfresa Pharma to Acquire 41 Products from Daiichi Sankyo 106
Amring Pharma Acquires Six ANDAs from Luitpold Pharma and AlphaForce 107
Egalet Acquires SPRIX Nasal Spray from Luitpold Pharma 108
CMIC CMO Completes Acquisition Of Research Equipment From Daiichi Sankyo 110
Sun Pharma Acquires Ranbaxy Labs for USD4 Billion 111
Daiichi Sankyo Acquires Majority Stake in Ambit Biosciences 114
Daiichi Sankyo Acquires Shanghai Xinshengyuan Pharma From Xinshengyuan Pharma 116
Daiichi Sankyo Plans To Acquire India-Based Pharma Company 117
Daiichi Sankyo Co Ltd, Key Competitors 118
Daiichi Sankyo Co Ltd, Key Employees 119
Daiichi Sankyo Co Ltd, Subsidiaries 121
Daiichi Sankyo Co Ltd, Joint Venture 124
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.